Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.5K
1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.6K
2.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating SARS-CoV-2 exposure in asymptomatic hospitalized children with cancer in Western Kenya: A retrospective analysis of serological data.

PloS one·2026
Same author

A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Author Correction: Magnon confinement in epitaxial antiferromagnetic oxide heterostructures.

Nature materials·2026
Same author

Breast milk antibody Fc signatures track with HIV transmission during breastfeeding in ART-naïve mothers.

iScience·2026
Same author

Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibition.

The Journal of biological chemistry·2026

Related Experiment Video

Updated: May 5, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.2K

Addressing genetic tumor heterogeneity through computationally predictive combination therapy.

Boyang Zhao1, Justin R Pritchard, Douglas A Lauffenburger

  • 11Computational and Systems Biology Program, 2The David H. Koch Institute for Integrative Cancer Research, Departments of 3Biology, and 4Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.

Cancer Discovery
|December 10, 2013
PubMed
Summary

Designing effective cancer treatments requires understanding tumor diversity. This study reveals that optimal drug combinations may not target the most common cancer cells directly, offering new strategies for complex tumors.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.3K

Related Experiment Videos

Last Updated: May 5, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.3K

Area of Science:

  • Oncology
  • Computational Biology
  • Pharmacology

Background:

  • Intratumoral heterogeneity poses a significant challenge in designing effective anticancer treatments.
  • Current treatment strategies often fail to account for the complex cellular diversity within tumors.

Purpose of the Study:

  • To develop and validate a methodology for designing optimized drug combinations that address intratumoral heterogeneity.
  • To investigate the principles of combination therapy design in the context of diverse tumor subpopulations.

Main Methods:

  • Utilizing RNA interference to model heterogeneous tumors.
  • Employing computational predictions to guide the selection of drug combinations.
  • Validating predictions through in vitro and in vivo experiments, including survival studies in a murine lymphoma model.

Main Results:

  • Demonstrated successful validation of computational predictions for optimized drug combinations against heterogeneous tumors.
  • Discovered that knowledge of the predominant tumor subpopulation is insufficient for determining the best drug combination.
  • Identified cases where optimal drug combinations do not include drugs targeting individual subpopulations most effectively.

Conclusions:

  • This study presents the first rational design of combination drug regimens to maximize tumor cell death.
  • The findings provide new insights into combination therapy design principles for complex tumors with intratumoral diversity.
  • The developed approach can inform the creation of superior drug regimens for challenging cancer types.